Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05687253 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery
A Phase 2 study, sponsored by Baudax Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT05687253 is a Phase 2 study that has completed, run by Baudax Bio. The registered enrollment target is 80 participants.
The verdict
NCT05687253, a Phase 2 study, has completed, sponsored by Baudax Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Assessment of Intubation conditions following administration of neuromuscular blocking agents; BX1000 (investigational) or rocuronium (active control).
Interventions
- DRUG BX1000
- DRUG Rocuronium Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2023-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05687253
The ClinicalTrials.gov registry entry for NCT05687253 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baudax Bio, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BX1000 is the first listed.
NCT05687253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05687253 about?
NCT05687253 is a clinical study titled "Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery". Assessment of Intubation conditions following administration of neuromuscular blocking agents; BX1000 (investigational) or rocuronium (active control).
What is the current status of trial NCT05687253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2022-10-25. Estimated completion is 2023-05-08.
What interventions are being tested in trial NCT05687253?
The interventions under investigation include: BX1000 (DRUG), Rocuronium Bromide (DRUG).
Who is sponsoring clinical trial NCT05687253?
This trial is sponsored by Baudax Bio, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.